> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher Awarded to Novimmune
- URL: https://www.fdaweb.com/priority-review-voucher-awarded-to-novimmune/
- Published: 2018-12-13T12:00:00.000Z
- Updated: 2026-09-15T00:50:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143035

*Federal Register* notice: FDA has issued a priority review voucher to Novimmune for its approved rare pediatric disease product application for Gamifant (emapalumab-lzsg) injection, indicated for treating adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-12-13/pdf/2018-27043.pdf?ref=fdaweb.com).